Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

Clinical susceptibility breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa for the ceftazidime-avibactam dosage regimen of 2,000/500 mg every 8 h (q8h) by 2-h intravenous infusion (adjusted for renal function) have been established by the FDA, CLSI, and EUCAST as susceptible (MIC, ≤8...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Autores principales: Nichols, Wright W., Stone, Gregory G., Newell, Paul, Broadhurst, Helen, Wardman, Angela, MacPherson, Merran, Yates, Katrina, Riccobene, Todd, Critchley, Ian A., Das, Shampa
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology 2018
Materias:
Clinical Therapeutics
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6201065/
https://ncbi.nlm.nih.gov/pubmed/30061279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02590-17
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares